21 Feb Decentralized clinical trial models: Are they here to stay?
Decentralized clinical trials rose in prominence during the COVID-19 pandemic. Are they here to stay?...
Decentralized clinical trials rose in prominence during the COVID-19 pandemic. Are they here to stay?...
Scientists have unveiled a road map for the development of a new vaccine that would be broadly protective against all coronaviruses....
The pandemic has revealed the impact of health disparities, so there's an added emphasis for the healthcare industry to focus on diversity, equity, and inclusion (DEI) efforts. ...
An economist, educator and leader, Chancellor Blank passed away February 17....
The FDA chooses drug optimization as the preferred blueprint for cancer trials. departing from the maximum tolerated dose model....
The US Food and Drug Administration (FDA) will soon require researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants....
It is impossible to view a trial as being of high quality without adequate representation of all patient populations....
When it comes to curing cancer, President Joe Biden is shifting that sentiment into full throttle. And Dr. Monica Bertagnolli is taking up the challenge....
In the future, there are benefits to be gained from collaborations between academic medical centers and industry to solve new problems across the spectrum of clinical research....
Dr. Eva Vivian, a breast cancer survivor, is a strong proponent of preventive medicine, both professionally and for her own health. So when the opportunity arose for Vivian to join a clinical trial testing a vaccine meant to prevent breast cancer development and recurrence, she...